Citations

Clear

40 citation(s) found for "Satomi, J".

Intracranial dural arteriovenous fistulas with perimedullary venous drainage: analysis of the multinational CONDOR registry
Potgieser, Adriaan R. E., Hallak, Hana , Connor, Michelle, Yuan, Jane , Lanzino, Giuseppe, Kim, Louis J., Levitt, Michael R., Samaniego, Edgar A., Alaraj, Ali, Starke, Robert M., Abla, Adib A., Koch, Matthew, Sheehan, Jason P., Gross, Bradley A., Satomi, Junichiro, Tada, Yoshiteru , Bulters, Diederik O., Hosainey, Sayied Abdol Mohieb , Du, Rose, Lawton, Michael T., Abecassis, Isaac Josh, Amin-Hanjani, Sepideh, Nguyen, Quang, Osbun, Joshua W., Zipfel, Gregory J., Dijk, J. Marc C. van, Dijk, J. Marc C. van , van DijK, J Marc C , Moniz‐Garcia, Diogo , Lanzino, Giuseppe , Kim, Louis J. , Levitt, Michael R. , Hayakawa, M. , Samaniego, Edgar A , Alaraj, Ali , Starke, Robert M. , Abla, A, Koch, Matthew J. , Dagra, Abeer , Sheehan, Jason P. , Derdeyn, Colin P. , Gross, Bradley , Satomi, J, Bulters, Diederik , Du, Rose , Lawton, Michael T. , Ding, Dale , Amin-Hanjani, Sepideh , Nguyen, Quang, Osbun, Joshua W , Zipfel, Gregory J.

Mayo Clinic

Journal of Neurosurgery | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-7

10.3171/2026.2.jns252734 | PMID 42566799 Get It

OBJECTIVE Cognard type V dural arteriovenous fistulas (dAVFs), defined by spinal perimedullary venous drainage, represent a rare and aggressive neurovascular pathology. Comprehensive multicenter data remain scarce. The authors present the largest multicenter analysis to date, characterizing presentation, radiology, treatment, complications, and functional outcomes of Cognard type V dAVFs. METHODS The authors retrospectively analyzed patients with angiographically confirmed Cognard type V dAVFs from the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR), spanning 16 academic centers. Patient demographics, imaging features, treatment strategies, procedural complications, and modified Rankin Scale (mRS) scores were recorded. RESULTS Among 1077 patients with dAVFs, 37 (3%) had Cognard type V lesions. The mean patient age was 57 years, and 59.5% of patients were male. Most presented with nonhemorrhagic neurological deficits (68%), while 14% had hemorrhage. The most common location was the foramen magnum (32%). Embolization was the primary treatment in 67% of cases, complete obliteration was achieved in 71% of cases. Upfront microsurgery was performed in 22% of patients (obliteration rate 88%), and radiosurgery in 14% (success rate 40%). Salvage treatment further improved obliteration outcomes. Temporary complications occurred in 8% of patients (3/37): 2 with transient neurological deficits postembolization and 1 with transient hydrocephalus after surgery. Permanent complications were observed in 3% (1/37) due to treatment-related hemorrhage. At the last follow-up (mean 2.4 years), 69% (24/35) of patients maintained or improved to an mRS score ≤ 2. No deaths occurred. Functional improvement was seen in 29% (10/35), while mRS decline was in 40% of patients (14/35), all unrelated to the dAVF itself. CONCLUSIONS Cognard type V dAVFs carry a high risk of neurological morbidity. However, favorable functional outcomes are achievable with timely, multimodal intervention. Complication rates remain low, with most being transient. These data support aggressive but tailored management to prevent permanent disability in this high-risk population.
E-329 Natural history, angioarchitecture and outcomes of pediatric dural arteriovenous fistulas: insights of the consortium of dural arteriovenous fistulas outcomes research (CONDOR)
Gudino, A, Hallak, H, Rivadeneira-Limongi, A , Gudino, L, Hayakawa, M, Chen, C, Sheehan, J, Abecassis, I, Levitt, M, Bulters, D, Fox, W, Smith, J, Sanchez, S, Polifka, A, Gross, B, Amin-Hanjani, S, Alaraj, A, Kwasnicki, A, Starke, R, Dijk, J van, Potgieser, A, Satomi, J, Tada, Y, Phelps, R, Figueroa, M Hinojosa, Godoy, M, Manrique, J, Abla, A, Winkler, E, Lai, P Rosalind, Zipfel, G, Samaniego, E, Gudino, Andres , Hayakawa, M, Sheehan, J P, Bulters, Diederik , Polifka, Adam , Amin-Hanjani, Sepideh , Alaraj, Ali , Kwasnicki, Amanda , Starke, R, van DijK, J Marc C , Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Y, Hinojosa-Figueroa, Mario S. , Abla, Adib A. , Lai, Pui Man Rosalind , Zipfel, Gregory J.

Mayo Clinic

SNIS 23rd Annual Meeting Electronic Poster Abstracts | July 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: A309.2-A310

10.1136/jnis-2026-snis.433 Get It

Research through Evaluation for Large Language Model in Patient-Clinician Communications
Holmes, Jason, Hobson, Jared, Bennett, Alexandra, McKone, Elizabeth L. , Ebner, Daniel, Shiraishi, Satomi, Patel, Samir H. , Yu, Nathan Y. , Hallemeier, Chris L., Ball, Brooke E., Waddle, Mark, Liu, Wei, Hao, Yuexing , Holmes, Jason , Routman, David M. , Kalantari, Saleh , Ghassemi, Marzyeh

Mayo Clinic

No container title available | June 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9735115/v1 | PMID 42370275 Get It

Abstract Large Language Models (LLMs) demonstrate strong capabilities in healthcare applications. However, recruiting human evaluators to assess usability and effectiveness becomes challenging in the large-scale LLM-generated outcomes. Existing metrics are often outdated for evaluating LLM-based healthcare technologies. This paper proposes a Research through Evaluation (RtE) approach that can refine metrics and improve assessments of LLM-generated outputs. We deploy RtE in a retrospective comparative study of prostate cancer patient inquiries, comparing responses from human clinical care teams with those generated by a GPT-4-based in-basket bot. Through three rounds of co-evaluations with clinical professionals and an LLM-as-graders study with four LLMs, the RtE method shows that starting with small, iterative evaluations helps human graders adjust metrics to suit their daily practices better. Additionally, in the LLM-as-graders study, LLMs exhibit similar behavior, preferring the in-basket bot's responses over the clinical care team. Our methodology and findings demonstrate that the RtE method can enhance the transparency and robustness of evaluation metrics for LLM-generated content, with the potential to generalize to evaluations in other clinical practices.
Systemic Cardiovascular Factors and Outcomes in Dural Arteriovenous Fistulas: Insights From the CONDOR Registry
Santos, Alejandro N. , Sanikommu, Sai , Dawoud, Bashar , Hallak, Hana , Gross, Bradley A. , Levitt, Michael R. , Wipplinger, Christoph , Lanzino, Giuseppe , Chen, Ching‐Jen , Abecassis, Isaac Josh , Ding, Dale , Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru , Chatterjee, Arindam R., Dijk, J. Marc C. van , Nguyen, Quang N., Kim, Louis J. , SHEEHAN, J, Luther, Evan, Osbun, J, Zipfel, Gregory J., Starke, Robert M., Santos, Alejandro N. , Samaniego, Edgar A , Alaraj, Ali , Tada, Yoshiteru , Chatterjee, Arindam R , van DijK, J Marc C , Amin-Hanjani, Sepideh , Kim, Louis J. , Sheehan, Jason , Fox, W Christopher , Du, Rose , Osbun, Joshua W , Zipfel, Gregory J , Levitt, Michael R , Ding, Dale , Lanzino, Giuseppe , Chen, Ching-Jen , Abecassis, Isaac Josh , Gross, Bradley , Alaraj, Ali , Nguyen, Quang, Hayakawa, M. , Zipfel, Gregory J. , Starke, Robert M.

Mayo Clinic

Stroke | May 11, 2026 | Volume: 57 | Issue: 8 | Pages: 2351-2363

10.1161/strokeaha.126.055466 | PMID 42109146 Get It

BACKGROUND: Hemorrhagic risk in dural arteriovenous fistulas (dAVFs) is largely determined by venous anatomy, but the contribution of systemic cardiovascular factors and their medical therapy remains poorly defined. This study examined associations between cardiovascular risk factors and antithrombotic use and hemorrhagic presentation, angiographic obliteration, and early functional outcomes after treatment. METHODS: We analyzed 1350 adults with intracranial dAVFs from the international Consortium for Dural Arteriovenous Fistula Outcomes Research registry, which retrospectively accrued cases across 14 centers in 4 countries between 1990 and 2017. Demographics, cardiovascular comorbidities, antithrombotic use, angioarchitectural features, treatment strategies, and follow-up outcomes were collected from prospectively maintained databases. Primary end points were hemorrhagic presentation, angiographic obliteration, and 90-day functional status after treatment. Univariable and multivariable logistic regressions were performed with model-specific adjustments. RESULTS: Hemorrhage occurred in 375 patients (27.8%) and was most strongly associated with high-grade dAVF classification and male sex; antithrombotic therapy was associated with lower odds of hemorrhagic presentation. Other cardiovascular risk factors showed no independent relationship with bleeding. Angiographic obliteration was achieved in 621 of 845 patients (73.5%). Hemorrhagic onset, high dAVF grade, and surgical treatment were independently associated with angiographic obliteration, whereas smoking and embolization demonstrated only nonsignificant trends after adjustment. At 90 days, 934 patients (88.9%) were functionally independent. Baseline modified Rankin Scale score was the strongest factor associated with 90-day functional outcome, while neither cardiovascular comorbidities nor treatment modality independently influenced functional status. CONCLUSIONS: In this large multicenter dAVF cohort, hemorrhagic presentation was most strongly associated with venous angioarchitecture. Male sex and antithrombotic therapy were also independently associated with hemorrhagic presentation. Angiographic obliteration was common, particularly among surgically treated lesions, and 90-day functional outcome was most strongly associated with baseline functional status.
Microsurgical management of tentorial dural arteriovenous fistula: an analysis from the Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR)
Hallak, Hana , Connor, Michelle, Lanzino, Giuseppe, Kim, Louis, Levitt, Michael R., Samaniego, Edgar, Amin-Hanjani, Sepideh, Alaraj, Ali, Starke, Robert M., Abla, A, Koch, Matthew, Sheehan, Jason P., Gross, Bradley A., Satomi, J, Tada, Yoshiteru , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Bulters, Diederik O., Du, Rose, Lawton, Michael, Abecassis, Isaac Josh, Osbun, Joshua W., Zipfel, Gregory J., Bulters, Diederik , van DijK, J Marc C , Bulters, Diederik O , Lanzino, Giuseppe , Kim, Louis J. , Levitt, Michael R. , Hayakawa, M. , Amin-Hanjani, Sepideh , Alaraj, Ali , Starke, Robert M. , Koch, Matthew J. , Dagra, Abeer , Sheehan, Jason P. , Derdeyn, Colin P. , Gross, Bradley , Du, Rose , Lawton, Michael T. , Osbun, Joshua W , Zipfel, Gregory J.

Mayo Clinic

Journal of Neurosurgery | April 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.3171/2025.11.jns251185 | PMID 41996712 Get It

OBJECTIVE Dural arteriovenous fistulas (dAVFs) are rare cerebrovascular anomalies. Tentorial dAVFs (TDAVFs) have more aggressive features, making them prone to symptomatic presentations and hemorrhage. TDAVFs are heterogenous and require tailored surgical approaches. Presented is a multicenter analysis of TDAVF surgical outcomes. METHODS The Consortium for Dural Arteriovenous Fistula Outcomes Research (CONDOR) consortium compiled data on dAVFs from 16 international centers from 1990 to 2021 retrospectively. Microsurgical treatment success was defined as angiographically confirmed complete obliteration of the fistula or discontinuation of cortical venous drainage (CVD) in high-grade TDAVFs. TDAVF subtypes and tailored surgical approaches were reviewed. RESULTS Of 1360 patients in CONDOR, 161 had TDAVFs and 27% (44/161) of these patients underwent surgical management, with the majority (52% [23/44]) receiving surgery as a salvage treatment following failed embolization. The mean age (SD) of this cohort was 56 (15) years, and 68% (30/44) were male. In total, 91% (40/44) of surgically treated patients presented with aggressive symptoms: 64% (28/44) presented with hemorrhage and 27% (12/44) with nonhemorrhagic neurological deficit (NHND). The median (IQR) duration from symptom onset to diagnosis was 1 (1–4) day. The median time (IQR) between diagnosis and surgery was 15 (3–80) days. Surgical approaches varied across the cohort, with the retrosigmoid being the most common (44% [18/41]), followed by the midline suboccipital (24% [10/41]) and occipital (15% [6/41]) approaches. Perioperative complications occurred in 11% (5/44) of cases, as well as permanent neurological deficits in 2% (1/44). Surgical success was achieved in 90% of patients (38/42). During the mean 3-year follow-up, 2 patients experienced a recurrence of their fistula including representation of CVD (2/38 [5%]) and 1 patient had a new NHND (1/43 [2%]). Shorter symptom duration was significantly associated with success (15.6 vs 181.5 days, p = 0.001). Primary versus salvage microsurgery showed no difference in outcomes. Both patients with recurrent fistula were effectively treated with Gamma Knife radiosurgery. CONCLUSIONS Resection is safe and durable for the treatment of TDAVF not otherwise amenable to embolization. It can achieve a high degree of success with a low rate of perioperative complications and permanent neurological deficits, benefits far exceeding the risks associated with TDAVF natural history or management with less effective modalities.
Large Language Model and Natural Language Processing Approach to Identify Cancer Recurrence From Pathology Reports
Bayona, D., Ebner, Daniel K., Ekama, Lydia, Talom, Benjamin K., Borras-Osorio, Mariana, Lozko, Yuliia, Namazi, Javad, Waddle, Mark R. , Bayona, Diego , Shiraishi, Satomi , Borras-Osorio, Mariana , Mastroleo, Federico , Waddle, Mark R , Routman, David M , Ebner, Daniel, Shiraishi, Satomi , Osorio, Mariana Borras, Lozko, Yuliia, Routman, David M.

Mayo Clinic

JCO Clinical Cancer Informatics | March 25, 2026 | Volume: 10 | Issue: 1 | Pages: No page available

10.1200/cci-25-00167 | PMID 41881064 Get It

PURPOSE Cancer recurrence is a critical outcome for patients and physicians. Retrospective cancer recurrence data can evaluate recurrence-directed treatment and generate novel interventions targeting recurrent cancers. However, large cancer databases do not provide recurrence-related information, stymying study at scale, and consequently require significant manual record review. Automated evaluation of records may allow for the rapid generation of easily analyzed data sets, accelerating the evaluation of recurrence altogether. METHODS Patients treated with radiation therapy at one tertiary referral center from 2010 to 2018 with a verified cancer status (cancer recurrence v no cancer recurrence) were identified. Patients with recurrent disease were initially identified through manual record review, and the associated pathology report was collected. Google Automated Machine Learning with Natural Language Processing (AutoNLP) and Google Gemini 1.5 Pro were used to generate a model for binary classification, with comparison to the gold-standard manually developed data set. RESULTS A total of 7,054 patients were identified. 3,431 (48.6%) were female, with a median age of 64 years. Head and neck (1,482, 21%), breast (1,480, 21%), upper GI (1,307, 18.5%), and lung/thorax (1,107, 15.7%) were the most common disease sites. Recurrence was verified for 1,546 patients (21.9%) using pathology reports, of which 1,249 positive cases were paired with 651 negative pathology reports for model development. Google Gemini 1.5 Pro consistently outperformed AutoNLP across all measurements of accuracy, generating a greater absolute difference in precision, recall, negative predictive value, and specificity, and a higher likelihood of correct classification at the individual level, rendering Gemini superior in recurrence status extraction. CONCLUSION AutoNLP and Google Gemini 1.5 Pro are promising tools for identifying recurrence from pathology reports, with the latter demonstrating superior overall performance, making it particularly suitable for clinical translation.
Expanding the molecular grading criteria in IDH-mutant astrocytoma
Virata, Michael , Samanamud, Jorge , Slocum, Connie, Kandoi, Shrishtee , Nguyen, Phuong , Savani, Milan R. , Shi, Diana D, Sharma, Sachein , Hiya, Satomi , Maldonado-Díaz, Carolina , Clare, Kevin, Vij, Meenakshi, Mir, Ema, Nishikawa, Y , Umphlett, Melissa , Yong, Raymund L. , Bederson, Joshua B. , Silva-Hurtado, Thenzing J. , Brem, Steven, Hambardzumyan, Dolores, Snuderl, Matija, Viapiano, Mariano S. , McBrayer, Samuel K. , Hatanpaa, Kimmo J. , Tsankova, Nadejda M. , Richardson, Timothy E. , Virata, Michael Christian , Samanamud, Jorge , Nguyen, Phuong , Yokoda, Raquel T , Vij, Meenakshi , Mir, Ema , Yong, Raymund L , Silva-Hurtado, Thenzing J , Brem, Steven , Hambardzumyan, Dolores , Snuderl, Matija , Viapiano, Mariano S , Abdullah, Kalil G , McBrayer, Samuel K , Tsankova, Nadejda M , Richardson, Timothy E , Shi, Diana D. , Yokoda, Raquel T. , Snuderl, Matija , Walker, Jamie M.

Mayo Clinic

Neuro-Oncology | March 24, 2026 | Volume: 28 | Issue: 8 | Pages: 1921-1932

10.1093/neuonc/noag069 | PMID 41903203 Get It

Abstract Background IDH-mutant astrocytomas are classified as WHO grade 4 in the presence of conventional high-grade histologic features and/or homozygous CDKN2A/B deletion in the 5th edition of the WHO Classification of Central Nervous System Tumour guidelines. However, work over the past decade has indicated a number of other molecular alterations that warrant consideration as potential prognostic markers. Methods We used univariate Kaplan-Meier and multivariate Cox proportional hazards regression analysis to evaluate the prognostic effects of homozygous CDKN2A/B deletion, CDK4 amplification, CCND2 amplification, PDGFRA amplification/mutation, PIK3R1 mutation, PIK3CA mutation, MYCN amplification, EGFR amplification/mutation, TERT promoter mutation, and grade 4 histologic features in two independent cohorts of WHO grade 2-4 IDH-mutant astrocytoma (n = 840 and n = 367). Results The presence of CDK4 amplification, CCND2 amplification, PDGFRA alteration, PIK3R1 mutation, MYCN amplification, and EGFR alteration were each associated with reduced overall survival compared to WHO grade 2/3 astrocytomas without these molecular features. 17.7% (148/837) of otherwise grade 2/3 astrocytomas had one or more of these molecular criteria, with resulting intermediate clinical outcome in terms of overall survival (median survival of 67.3-82.0 months) compared to grade 2/3 astrocytomas without these molecular features (median survival of 135.0-140.7 months) and grade 4 astrocytomas (median survival of 35.3-45.0 months). Conclusions The presence of CDK4, CCND2, PDGFRA, PIK3R1, MYCN, and EGFR alterations result in an intermediate patient survival in IDH-mutant astrocytoma. Adding these molecular alterations should be considered in future diagnostic classification systems to improve stratification of high-risk patients.
Using large language models for grading CTCAE toxicity after radiation therapy for prostate cancer.
Wilson, Renthony, Osorio, Mariana Borras, Patel, Shiv, Peterson, Sarah, Zhou, Mi , Waddle, Mark R. , Mastroleo, Federico , Osorio, Mariana Borras, Shiraishi, Satomi , Foong, Anthony , Routman, David M. , Zhou, Mi

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: 357-357

10.1200/jco.2026.44.7_suppl.357 Get It

357 Background: Prostate cancer (PCa) is the most incident cancer in adult males in the United States, and the second highest in the world. CTCAE is the standardized method to grade the severity of treatment-related adverse events (AEs), but are tedious to collect and subject to inter-observer variability. This study aimed to evaluate the performance of LLMs in automatically extracting and grading CTCAE toxicities from clinical notes and patient-reported outcomes of PCa patients from a clinical trial. Methods: A total of 55 patients from NCT02874014 trial, undergoing proton therapy (PT) for localized PCa, were included. The ground truth of CTCAE graded toxicities was obtained from the trial’s results. Clinical notes within 3 days, and the most recent patient questionnaires within 90 days of toxicity assessment were retrieved from the electronic health record. A comprehensive prompt was developed to extract and CTCAE grade toxicities from the retrieved records. LLMs used for this analysis were OpenAI GPT-4o and Gemini 2.0 Flash. Phase 1 evaluated both LLMs' performance against the ground truth. To ensure the metrics reflected the models’ performance based only on the information available in the text provided, cases where both LLMs contradicted the ground truth were manually reviewed. Phase 2 recalculated LLMs' performance metrics using this adapted ground truth. A conservative stepwise ensemble model was developed to leverage the complementary strengths of both LLMs. Results: In the conservative stepwise ensemble model, Gemini 2.0 Flash served as the initial screening platform to identify AEs in step 1. All cases with identified toxicity events were then reviewed and confirmed using OpenAI GPT-4o in step 2. This effectively reduced false positive rates while preserving high sensitivity. The ensemble model achieved strong performance metrics: binary accuracy (0.954), sensitivity (0.961), specificity (0.953), F1 score (0.836), and grade accuracy (0.932). Conclusions: This study demonstrates the feasibility of the use of LLMs for extraction and CTCAE toxicity grading in PCa patients treated with RT. The ensemble model achieved strong performance metrics. Further validation is needed for other cancer diagnosis and treatment modalities. Phase Model Binary Accuracy Precision Sensitivity Specificity F1 Score Grade Accuracy 1 Gemini 0.946 0.672 1.000 0.939 0.804 0.919 1 OpenAI 0.940 0.785 0.637 0.978 0.703 0.895 2 Gemini 0.956 0.735 1.000 0.950 0.848 0.927 2 OpenAI 0.954 0.917 0.679 0.991 0.780 0.903
Comparison of partial breast radiation modalities in women with early-stage breast cancer: a target trial emulation
Shumway, Dean A. , Corbin, Kimberly S. , Farah, Magdoleen H. , Fleti, Farah, Hasan, Bashar , Firwana, Mohammed , Saadi, Samer , Nayfeh, Tarek , Hegazi, Moustafa , Waddle, Mark R. , Amundson, A., Vallow, Laura A., Mutter, Robert W. , Shiraishi, Satomi , Farah, Magdoleen H , Fleti, Farah , Hasan, Bashar , Firwana, Mohammed M , Saadi, Samer , Nayfeh, Tarek , Hegazi, Moustafa , Waddle, Mark R , Amundson, Adam C., Hieken, Tina J , Park, Sean S , Mutter, Robert W , Murad, M Hassan , Shumway, Dean A , Shiraishi, Satomi , Vargas, Carlos E, Oladeru, Oluwadamilola T. , Hieken, Tina J. , Park, Sean S. , Murad, M. Hassan , Wang, Zhen

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 5, 2025 | Volume: 118 | Issue: 4 | Pages: 691-698

10.1093/jnci/djaf346 | PMID 41352976 Get It

Abstract Background Partial breast irradiation (PBI) is an effective treatment for early-stage breast cancer. However, evidence comparing different PBI modalities is limited. Methods This trial emulation uses electronic health records from a multi-state large tertiary health system. Three PBI modalities were compared: proton radiation therapy, photon radiation therapy, and applicator-based brachytherapy. Inverse probability weighting (IPW) was used to balance confounders. The primary outcome was ipsilateral breast recurrence (IBR). Results Between 2013 and 2023, 1041 women with early-stage breast cancer were treated with PBI. Of these, 1026 patients were included in the analyses. The median age was 66 years; 22.51% had ductal carcinoma in situ (DCIS), and 97.56% were estrogen receptor positive. With median follow-up of 38.2 months, the rate of IBR in the overall group was 3.05% (95% confidence interval [CI] = 1.99% to 4.65%) at 3 years. After IPW, compared with photon PBI, the hazard ratio for IBR for proton PBI was 2.11 (95% CI = 0.70 to 6.33) and for brachytherapy, 3.86 (95% CI = 1.39 to 10.69). Compared with proton PBI, the hazard ratio for IBR for brachytherapy was 1.83 (95% CI = 0.88 to 3.81). IBR risk was similar across PBI modalities for patients with tumor size ≤ 10 mm and in patients treated for DCIS. Among patients with tumor size >10 mm, the hazard ratio for IBR for brachytherapy was 7.64 (95% CI = 1.64 to 35.58) and 3.59 (95% CI = 1.22 to 10.56) relative to photons and protons, respectively. Conclusion PBI with applicator-based brachytherapy was associated with higher IBR than photon or proton PBI in patients with tumor size > 10 mm, suggesting the need for more careful PBI patient selection for this modality.
O-039 Consortium for dural arteriovenous fistula outcomes research (CONDOR): endovascular treatment of tentorial dural arteriovenous fistulae
Hallak, Hana , Chalouhi, Nohra , Gross, Bradley A. , Satomi, Junichiro, Levitt, M, Sheehan, Jason , Zipfel, Gregory J. , Chatterjee, A, Gross, Bradley , Dijk, J Van, Bulters, Diederik , Hayakawa, M. , Lanzino, Giuseppe , Levitt, M, Alaraj, Ali , Osbun, Joshua W

Mayo Clinic

SNIS 22nd annual meeting oral abstracts | July 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: A33-A34

10.1136/jnis-2025-snis.39 Get It